← Browse by Condition
Medical Condition

solid tumor adult

Total Trials
20
Recruiting Now
20
Trial Phases
Phase 1, Phase 2, Phase 3, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for solid tumor adult sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — solid tumor adult Clinical Trials

How many clinical trials are currently recruiting for solid tumor adult?
ClinicalMetric currently tracks 20 actively recruiting clinical trials for solid tumor adult, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 20. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for solid tumor adult?
solid tumor adult research spans Phase 1 (15 trials), Phase 2 (10 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a solid tumor adult clinical trial?
Eligibility criteria for solid tumor adult trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
15
Phase 2
10
Phase 3
1
Top Sponsors
Second Affiliated Hospital of Guangzhou Medical University 4 trials
Sairopa B.V. 1 trial
QuantumLeap Healthcare Collaborative 1 trial
DualityBio Inc. 1 trial
Immatics Biotechnologies GmbH 1 trial

Recruiting Clinical Trials

NCT05856981 Phase 1
Recruiting
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Enrollment
130 pts
Location
United States, Belgi...
Sponsor
Sairopa B.V.
View Trial →
NCT06478108 Phase 2, Phase 3
Recruiting
Interventional Software for Multi-immunotherapy of Solid Tumors
Enrollment
60 pts
Location
China
Sponsor
Second Affiliated Hospital of ...
View Trial →
NCT05868226 Phase 1, Phase 2
Recruiting
PRE-ISPY Phase I/II Oncology Platform Program
Enrollment
280 pts
Location
United States
Sponsor
QuantumLeap Healthcare Collabo...
View Trial →
NCT06554795 Phase 1, Phase 2
Recruiting
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
Enrollment
360 pts
Location
United States, Austr...
Sponsor
DualityBio Inc.
View Trial →
NCT05958121 Phase 1, Phase 2
Recruiting
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
Enrollment
400 pts
Location
Germany, Netherlands
Sponsor
Immatics Biotechnologies GmbH
View Trial →
NCT04803318 Phase 2
Recruiting
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Enrollment
100 pts
Location
China
Sponsor
Second Affiliated Hospital of ...
View Trial →
NCT06292845
Recruiting
Ex Vivo Tumor Visualization and Resection Margin Assessment Using Topically Applied Fluorescent Imaging Agents
Enrollment
200 pts
Location
Netherlands
Sponsor
Erasmus Medical Center
View Trial →
NCT04196257 Phase 1
Recruiting
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Enrollment
50 pts
Location
United States
Sponsor
Bio-Path Holdings, Inc.
View Trial →
NCT06895733 Phase 1, Phase 2
Recruiting
Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)
Enrollment
65 pts
Location
China
Sponsor
Tianjin Medical University Sec...
View Trial →
NCT05055609 Phase 1
Recruiting
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
Enrollment
94 pts
Location
United States
Sponsor
Trethera
View Trial →
NCT06625775 Phase 1
Recruiting
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Enrollment
392 pts
Location
United States, Austr...
Sponsor
TheRas, Inc., d/b/a BBOT (Brid...
View Trial →
NCT06195384 Phase 1
Recruiting
Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors
Enrollment
30 pts
Location
China
Sponsor
Second Affiliated Hospital of ...
View Trial →
NCT05669430 Phase 1, Phase 2
Recruiting
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Enrollment
365 pts
Location
United States
Sponsor
GV20 Therapeutics
View Trial →
NCT06326411 Phase 1
Recruiting
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Enrollment
230 pts
Location
United States, Austr...
Sponsor
Nested Therapeutics, Inc
View Trial →
NCT04665206 Phase 1, Phase 2
Recruiting
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Enrollment
434 pts
Location
United States, Austr...
Sponsor
Vivace Therapeutics, Inc
View Trial →
NCT03778814 Phase 1
Recruiting
TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
Enrollment
30 pts
Location
China
Sponsor
Second Affiliated Hospital of ...
View Trial →
NCT03823144
Recruiting
Intravital Microscopy in Human Solid Tumors
Enrollment
85 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →
NCT06350539
Recruiting
Personalized Models for Cancer Research
Enrollment
500 pts
Location
United States
Sponsor
New York Stem Cell Foundation ...
View Trial →
NCT06598007 Phase 1, Phase 2
Recruiting
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Enrollment
78 pts
Location
United States
Sponsor
Crossignal Therapeutics, Inc.
View Trial →
NCT06088004 Phase 1, Phase 2
Recruiting
Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Enrollment
218 pts
Location
China
Sponsor
Suzhou Abogen Biosciences Co.,...
View Trial →

Related Conditions

refractory cancer (3) endometrial cancer (2) metastatic breast cancer (2) her2 positive metastatic breast cancer (2) her2 mutation related tumors (2) solid tumor (2) oncology (2) nsclc (2) metastatic solid tumor (1) crc colorectal cancer (1) rcc clear cell adenocarcinoma (1) nsclc advanced non small cell lung cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology